Helen Michelakakis

Helen Michelakakis

Auto-generated profile, based on publicly available information

Helen Michelakakis

Department of Enzymology and Cellular Function, Institute of Child Health, Athens, Greece

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2002 in Clinical Biochemistry
Verified
Journal Article
Closed access
KSKleopatra H Schulpis
Kleopatra H Schulpis
JTJoanna Tjamouranis
Joanna Tjamouranis
George-Albert KarikasGeorge-Albert Karikas
George-Albert Karikas
HMHelen Michelakakis
Helen Michelakakis
STStylianos Tsakiris
Stylianos Tsakiris

1 September 2020 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
EDEvangelia Dimitriou
Evangelia Dimitriou
MMMarina Moraitou
Marina Moraitou
MCMónica Cozar
Mónica Cozar
JSJenny Serra-Vinardell
Jenny Serra-Vinardell
LVLluïsa Vilageliu
Lluïsa Vilageliu
HMHelen Michelakakis
Helen Michelakakis
Gaucher disease (GD) is characterized by a marked phenotypic and genetic diversity. It is caused by the functional deficiency of the lysosomal enzyme β-glucocerebrosidase (GCase), which in most instances results from mutations in the GBA1 gene and over 500 different disease causing mutations have been described. We present the biochemical and molecular findings in 141 GD cases (14 were siblings) with the three types of the disorder diagnosed in Greece over the last 35 years. 111/141 (78%) GD patients were of Greek origin. The remaining patients were Albanian (24/141; 17%), Syrian (2/141; 1.4%), Egyptian (2/141; 1.4%), Italian (1/141; 0.7%) and Polish (1/141; 0.7%). Mutation analysis identified 28 different mutations and 37 different genotypes. Seven of the mutations were not previously reported (T231I, D283N, N462Y, LI75P, F81L, Y135S and T482K). The most frequent mutations were N370S, D409H;H255Q and L444P. Mutation D409H;H255Q was only identified in Greek and Albanian patients. Sixteen mutations, including the novel ones, were identified only in one allele. Although the N370S mutation was identified only in type 1 patients, not all of type 1 patients carried this mutation. Our results highlight the heterogeneity of Gaucher disease and support the Balkan origin of the double mutant allele D409H;H255Q.

20 January 2017
Verified
Book Chapter
Closed access
PDF file
IMIrene Mavridou
Irene Mavridou
EDEvangelia Dimitriou
Evangelia Dimitriou
MVMarie T. Vanier
Marie T. Vanier
LVLluisa Vilageliu
Lluisa Vilageliu
DGDaniel Grinberg
Daniel Grinberg
HMHelen Michelakakis
Helen Michelakakis

14 January 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
AMAnna Malekkou
Anna Malekkou
ISIoanna Sevastou
Ioanna Sevastou
GMGavriella Mavrikiou
Gavriella Mavrikiou
TGTheodoros Georgiou
Theodoros Georgiou
LVLluisa Vilageliu
Lluisa Vilageliu
ADAnthi Drousiotou
Anthi Drousiotou
Background: Mutations in the GBA gene that encodes the lysosomal enzyme acid β‐glucocerebrosidase cause Gaucher disease (GD), the most common lysosomal storage disorder. Most of the mutations are missense/nonsense, however, a few splicing mutations within or close to conserved consensus donor or acceptor splice sites have also been described. The aim of the study was to identify the mutation(s) in a Cypriot patient with type I GD.Methods: The genomic DNA of the proband was screened for nine common mutations using Polymerase chain reaction–restriction fragment length polymorphism (PCR–RFLP) analysis. All exons and exon‐intron boundaries, and the 5’UTR and 3’UTR regions of the GBA gene, were investigated by Sanger sequencing. RNA analysis was performed using standard procedures, and the abnormal transcript was further cloned into pGEM‐T‐Easy plasmid vector and sequenced. The relevant intronic region was further sequenced by the Sanger method to identify the genetic variant.Results: A novel point mutation, g.12599C > A (c.999 + 242C > A), was detected deep in intron 7 of the GBA gene. This type of mutation has been previously described for other diseases but this is the first time, as far as we know, that it is described for GD. This mutation creates a new donor splice site leading to aberrant splicing and resulting in the insertion of the first 239nt of intron 7 as a pseudoexon in the mRNA, creating a premature stop codon.Conclusion: This study expands the mutation spectrum of GD and highlights the importance of RNA sequencing for the molecular diagnosis of patients bearing mutations in nonexonic regions.

4 May 2017 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
EBEVANGELIA BOUNOUVI
EVANGELIA BOUNOUVI
APAnna Papadopoulou
Anna Papadopoulou
MVMarie T. Vanier
Marie T. Vanier
GNGeorgia Nyktari
Georgia Nyktari
SKSpyridon Kanellakis
Spyridon Kanellakis
ADArgyrios Dinopoulos
Argyrios Dinopoulos
Niemann-Pick type C disease (NPC) is an autosomal recessive, neurovisceral, lysosomal storage disorder with protean and progressive clinical manifestations, resulting from mutations in either of the two genes, NPC1 (~95% of families) and NPC2. Contrary to other populations, published evidence regarding NPC disease in Greece is sparse. The study population consisted of two Greek NPC patients and their extended pedigree. Patients’ clinical, biochemical, molecular profiles and the possible correlations are presented. Genotyping was performed by direct sequencing. Mutations’ origin was investigated through selected exonic NPC1 polymorphisms encountered more frequently in a group of 37 Greek patients with clinical suspicion of NPC disease and in a group of 90 healthy Greek individuals, by the use of Haplore software. Two novel NPC1 mutations, [IVS23 + 3insT (c.3591 + 3insT) and p. K1057R (c.3170A > C)] were identified and each mutation was associated with a specific haplotype. One of the patients was entered to early treatment with miglustat and has presented no overt neurological impairment after 11.5 years. The splicing mutation IVS23 + 3insT was associated in homozygocity with a severe biochemical and clinical phenotype. A possible founder effect for this mutation was demonstrated in the Greek Island, as well as a different origin for each novel mutation. Longitudinal follow-up may contribute to clarify the possible effect of early miglustat therapy on the patient compound heterozygous for the two novel mutations.

5 February 2021 in Children
Verified
Journal Article
Open access
PDF file
VKVASILIKI KARAVA
VASILIKI KARAVA
AKAntonia Kondou
Antonia Kondou
JOHN DOTISJOHN DOTIS
JOHN DOTIS
GSGeorgia Sotiriou
Georgia Sotiriou
SGSpyridon Gerou
Spyridon Gerou
NPNikoleta Printza
Nikoleta Printza
Methylmalonic acidemia and homocystinuria cobalamin C (cblC) type is the most common inborn error of the intracellular cobalamin metabolism, associated with multisystem involvement and high mortality rates, especially in the early-onset form of the disease. Hemolytic uremic syndrome (HUS) is a rare manifestation and needs to be distinguished from other causes of renal thrombotic microangiopathy. We describe a case of a 3-month-old infant, with failure to thrive, hypotonia and pallor, who developed HUS in the setting of cblC deficit, along with dilated cardiomyopathy, and presented delayed response to optic stimulation in visual evoked potentials, as well as enlarged bilateral subarachnoid spaces and delayed myelination in brain magnetic resonance imaging. Renal damage was reversed, while neurodevelopmental profile and eye contact improved after supplementation with parenteral hydroxycobalamin, oral folic acid, betaine and levocarnitine. Homozygous mutation of c.271dupA in the MMACHC gene was ultimately detected. In this report, we highlight the diagnostic challenges as well as the significance of early recognition and multidisciplinary management of this unusual condition. A brief review of published case reports of early-onset cblC deficit and related HUS is depicted, pointing out the initial clinical presentation, signs of renal damage and outcome, MMACHC gene type of mutations and accompanying extra-renal manifestations.